Jones PA et al. (1983) DNA modification, differentiation, and transformation. J Exp Zool228: 287–295 CASPubMed Google Scholar
Ando T et al. (2000) Decitabine (5-Aza-2'-deoxycytidine) decreased DNA methylation and expression of MDR-1 gene in K562/ADM cells. Leukemia14: 1915–1920 CASPubMed Google Scholar
Ley TJ et al. (1983) DNA methylation and globin gene expression in patients treated with 5-azacytidine. Prog Clin Biol Res134: 457–474 CASPubMed Google Scholar
Gattei V et al. (1993) In vitro and in vivo effects of 5-aza-2'-deoxycytidine (Decitabine) on clonogenic cells from acute myeloid leukemia patients. Leukemia7 (Suppl 1): 42–48 PubMed Google Scholar
Leone G et al. (2002) DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica87: 1324–1341 CASPubMed Google Scholar
Blanchard F et al. (2003) DNA methylation controls the responsiveness of hepatoma cells to leukemia inhibitory factor. Hepatology38: 1516–1528 CASPubMed Google Scholar
Silverman LR et al. (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol20: 2429–2440 CASPubMed Google Scholar
Saba H et al. (2004) First report of the phase III North American trial of decitabine in advanced myelodysplastic syndrome (MDS) [abstract]. Blood104: 23A Google Scholar
Kantarjian HM et al. (2004) Decitabine low-dose schedule (100 mg/m(2)/course) in myelodysplastic syndrome (MDS). Comparison of 3 different dose schedules. Blood104: 402A–403A Google Scholar
Issa J-P et al. (2004) Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood103: 1635–1640 CASPubMed Google Scholar
Kaminskas E et al. (2005) Approval summary azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res11: 3604–3608 CASPubMed Google Scholar
Saba H et al. Advanced myelodysplastic syndromes: patient subset results of a phase III trial comparing decitabine with supportive care [abstract]. J Clin Oncol23: 6543
Saiki JH et al. (1978) 5-Azacytidine in acute leukemia. Cancer42: 2111–2114 CASPubMed Google Scholar
Vogler WR et al. (1976) 5-Azacytidine (NSC 102816): a new drug for the treatment of myeloblastic leukemia. Blood48: 331–337 CASPubMed Google Scholar
Von Hoff DD et al. (1976) 5-Azacytidine. A new anticancer drug with effectiveness in acute myelogenous leukemia. Ann Intern Med85: 237–245 CASPubMed Google Scholar
Schiffer CA et al. (1982) Treatment of the blast crisis of chronic myelogenous leukemia with 5-azacitidine and VP-16–213. Cancer Treat Rep66: 267–271 CASPubMed Google Scholar
Lee EJ et al. (1990) Low dose 5-azacytidine is ineffective for remission induction in patients with acute myeloid leukemia. Leukemia4: 835–838 CASPubMed Google Scholar
Kornblith AB et al. (2002) Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol20: 2441–2452 CASPubMed Google Scholar
Schwartsmann G et al. (1997) Decitabine (5-Aza-2'-deoxycytidine; DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: preliminary observations. Leukemia11 (Suppl 1): 28–31 Google Scholar
Petti MC et al. (1993) Pilot study of 5-aza-2'-deoxycytidine (Decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results. Leukemia7 (Suppl 1): 36–41 PubMed Google Scholar
Willemze R et al. (1997) A randomized phase II study on the efects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893). Leukemia11 (Suppl 1): 24–27 Google Scholar
Wijermans PW et al. (1997) Continuous infusion of low-dose 5-Aza-2'-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia11 (Suppl 1): 19–23 Google Scholar
Wijermans PW et al. (2000) Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol18: 956–962 CASPubMed Google Scholar
Saba HI and Wijermans PW (2005) Decitabine in myelodysplastic syndromes. Semin Hematol42 (Suppl 2): S23–S31 CASPubMed Google Scholar
Miller KB (2000) Myelodysplastic syndromes. Curr Treat Options Oncol1: 63–69 CASPubMed Google Scholar
Candoni A et al. (2004) Targeted therapies in myelodysplastic syndromes: ASH 2003 review. Semin Hematol41: 13–20 CASPubMed Google Scholar
Mufti G et al. (2003) Myelodysplastic syndrome. Hematology (Am Soc Hematol Educ Program): 176–199
Alessandrino EP et al. (2002) Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica87: 1286–1306 PubMed Google Scholar
Cutler CS et al. (2004) A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood104: 579–585 CASPubMed Google Scholar
List A et al. (2005) Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med352: 549–557 CASPubMed Google Scholar
Lee EJ et al. (1990) Low dose 5-azacytidine is ineffective for remission induction in patients with acute myeloid leukemia. Leukemia4: 835–838 CASPubMed Google Scholar
Petti MC et al. (1993) Pilot study of 5-aza-2'-deoxycytidine (Decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results. Leukemia7 (Suppl 1): 36–41 PubMed Google Scholar
Issa J-P et al. (2005) Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol23: 3948–3956 CASPubMed Google Scholar
van den Bosch J et al. (2004) The effects of 5-aza-2'-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes. Leuk Res28: 785–790 CASPubMed Google Scholar